Genedrive plc (GB:GDR) has released an update.
Genedrive plc, a leader in point of care pharmacogenetic testing, has announced a multi-pronged fundraising effort aiming to secure a minimum of £6.0 million to support its operational growth and expedite the commercialization of its products in key markets, including the UK, Europe, and the Middle East. The company plans to fund clinical studies and regulatory submissions in the U.S., particularly for its AIHL test kit. The fundraising includes a mix of a placing, a financing offer on the REX platform, and an Open Offer to existing shareholders, all at a significant discount to the recent closing share price.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.
